Embecta (EMBC) - 2026 Q1 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In Q1 fiscal year 2026, Embecta generated approximately $261 million in revenue, reflecting a 0.3% decline year-over-year on an as-reported basis, or a 2% decline on an adjusted constant currency basis [15] - GAAP gross profit for Q1 2026 totaled $161.7 million with a margin of 61.9%, compared to $151.7 million and 60% in the prior year [19] - GAAP net income for Q1 2026 was $44.1 million, with earnings per diluted share of $0.74, compared to zero in the prior year period [22] Business Line Data and Key Metrics Changes - Adjusted constant currency pen needle revenue declined approximately 4.4%, while syringe revenue grew by approximately 5.3% and safety product revenue grew approximately 7.3% [17] - Contract manufacturing revenue declined approximately 16.7% due to continued insourcing by Becton Dickinson [18] Market Data and Key Metrics Changes - U.S. revenue for Q1 totaled approximately $131 million, reflecting a year-over-year decline of 7.6% on an adjusted constant currency basis, driven by lower pricing and volumes [15] - International revenue for Q1 totaled approximately $130 million, representing an increase of 8.4% on a reported basis, driven by strength across EMEA and Latin America [16] Company Strategy and Development Direction - The company is in the seed growth phase, focusing on staying competitive in core markets, selectively expanding the portfolio, and building financial flexibility through disciplined capital allocation [7] - A significant initiative is the brand transition to establish Embecta as an independent company, with over 95% of U.S. and Canadian revenue transitioned to the Embecta brand [8] Management's Comments on Operating Environment and Future Outlook - Management expects the recovery in China to be more weighted towards the second half of the fiscal year, with ongoing market dynamics impacting performance [16] - The company reaffirmed its financial guidance for the year, now expecting to be closer to the lower end of the guidance ranges due to incremental U.S. pricing headwinds [18][25] Other Important Information - The company is collaborating with over 30 pharmaceutical partners on GLP-1 therapies, with several partners already selecting Embecta as a supplier [10] - The company expects to generate between $180 million and $200 million in free cash flow for 2026, although closer to the low end of that range [26] Q&A Session Summary Question: Can you provide insights on U.S. business dynamics, pricing impacts, and the expected recovery in China? - Management noted a year-over-year decline in the U.S. driven by lower pricing and volume, with channel dynamics impacting results. They expect a recovery in China in the second half of the year [31][32] Question: What factors contributed to the strength in international markets? - Management attributed the growth in international markets to superior execution, particularly in Latin America, where a new large customer has driven growth [43] Question: Can you elaborate on the GLP-1 opportunity and the impact of oral therapies? - Management remains confident in the GLP-1 opportunity, noting that injectables have better weight loss profiles and that oral therapies are expanding the market rather than pulling patients away from injectables [36][39]